2024
Eligibility for Anti-Obesity Medications through Medicare for Older Adults with Overweight or Obesity
Chetty A, Khunte M, Chen A, Jastreboff A, Krumholz H, Lu Y. Eligibility for Anti-Obesity Medications through Medicare for Older Adults with Overweight or Obesity. American Heart Journal 2024, 278: 8. DOI: 10.1016/j.ahj.2024.09.022.Peer-Reviewed Original ResearchAnti-obesity medicationsOlder adultsType 2 diabetesNational Health and Nutrition Examination SurveyHealth and Nutrition Examination SurveyCardiovascular diseaseNutrition Examination SurveyOlder ageMale sexExamination SurveyMinority race/ethnicitySociodemographic statusPopulation of beneficiariesMedicare beneficiariesPost-MarchLow-incomeMedicare Part D.Medicare coverageMedicareStudy sampleWhite racePre-marchEligibility ratesObesityPooled dataTirzepatide for Obesity Treatment and Diabetes Prevention
Jastreboff A, le Roux C, Stefanski A, Aronne L, Halpern B, Wharton S, Wilding J, Perreault L, Zhang S, Battula R, Bunck M, Ahmad N, Jouravskaya I. Tirzepatide for Obesity Treatment and Diabetes Prevention. New England Journal Of Medicine 2024 PMID: 39536238, DOI: 10.1056/nejmoa2410819.Peer-Reviewed Original ResearchType 2 diabetesProgression to type 2 diabetesDose escalation periodRisk of progression to type 2 diabetesBody weightDoses of tirzepatideBaseline to weekOnce-weekly dosingOff-treatment periodSustained weight reductionYear of treatmentDiagnosis of type 2 diabetesAssigned doseDouble-blindPlacebo groupAdverse eventsTirzepatideTirzepatide groupsPlaceboCausal precursorsSafety signalsObesity treatmentSustained reductionDelay progression to type 2 diabetesObesitySurvodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™‐1 and ‐2)
Wharton S, le Roux C, Kosiborod M, Platz E, Brueckmann M, Jastreboff A, Hussain S, Pedersen S, Borowska L, Unseld A, Kloer I, Kaplan L, committees and investigators T. Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™‐1 and ‐2). Obesity 2024, 33: 67-77. PMID: 39495965, PMCID: PMC11664303, DOI: 10.1002/oby.24184.Peer-Reviewed Original ResearchTreatment of obesityBaseline BMIRandomized phase 3 clinical trialOnce-weekly subcutaneous injectionsPhase 3 clinical trialsBaseline to weekDouble-blind trialObesity-related complicationsBody weight reductionAbsence of T2DSystolic blood pressureLiver fat contentType 2 diabetesMagnetic resonance imagingMeasures of glycemiaSecondary endpointsDosing flexibilityProportion of participantsLifestyle modificationInvestigated glucagonSubcutaneous injectionBlood pressureBody compositionResonance imagingObesityDCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases
Handelsman Y, Anderson J, Bakris G, Ballantyne C, Bhatt D, Bloomgarden Z, Bozkurt B, Budoff M, Butler J, Cherney D, DeFronzo R, Del Prato S, Eckel R, Filippatos G, Fonarow G, Fonseca V, Garvey W, Giorgino F, Grant P, Green J, Greene S, Groop P, Grunberger G, Jastreboff A, Jellinger P, Khunti K, Klein S, Kosiborod M, Kushner P, Leiter L, Lepor N, Mantzoros C, Mathieu C, Mende C, Michos E, Morales J, Plutzky J, Pratley R, Ray K, Rossing P, Sattar N, Schwarz P, Standl E, Steg P, Tokgözoğlu L, Tuomilehto J, Umpierrez G, Valensi P, Weir M, Wilding J, Wright E. DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases. Metabolism 2024, 159: 155931. PMID: 38852020, DOI: 10.1016/j.metabol.2024.155931.Peer-Reviewed Original ResearchChronic kidney diseaseAtherosclerotic cardiovascular diseaseHeart failureMetabolic diseasesCardiorenal risk factorsEssentials of managementPractice recommendationsType 2 diabetesImprove patient outcomesVolunteer task forcePrimary care physiciansMetabolic comorbiditiesMultispecialty consensusOutcome trialsManagement of personsKidney diseaseLiver diseasePathophysiological pathwaysPulmonary diseaseRisk factorsSteatotic liver diseaseManagement of diabetesCardiovascular diseasePatient outcomesCare physicians
2023
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
Garvey W, Frias J, Jastreboff A, le Roux C, Sattar N, Aizenberg D, Mao H, Zhang S, Ahmad N, Bunck M, Benabbad I, Zhang X, investigators S, Abalos F, Manghi F, Zaidman C, Vico M, Aizenberg D, Costanzo P, Serra L, MacKinnon I, Hissa M, Vidotti M, Saraiva J, Alves B, Franco D, Moratto O, Murthy S, Goyal G, Yamasaki Y, Sato N, Inoue S, Asakura T, Shestakova M, Khaykina E, Troshina E, Vorokhobina N, Ametov A, Tu S, Yang C, Lee I, Huang C, Ou H, Freeman G, Machineni S, Klein K, Sultan S, Parsa A, Otero-Martinez J, Gonzalez A, Bhargava A, Brian S, Ince C, Plantholt S, Cole J, Lacour A, Vega D, de Souza J, Rohlf J, St. John R, Horowitz B, Audish H, Galindo R, Umpiperrez G, Ard J, Curtis B, Garvey W, Fraser N, Mandry J, Mohseni R, Mayfield R, Powell T, Vance C, Ong S, Lewy-Alterbaum A, Murray A, Al-Karadsheh A, Yacoub T, Roberts K, Fried D, Rosenstock J, Pulla B, Bode B, Frias J, Klaff L, Brazg R, Van J, Tan A, Briskin T, Rhee M, Chaicha-Brom T, Hartley P, Nunez L, Cortes-Maisonet G, Soucie G, Hsia S, Jones T. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. The Lancet 2023, 402: 613-626. PMID: 37385275, DOI: 10.1016/s0140-6736(23)01200-x.Peer-Reviewed Original ResearchConceptsType 2 diabetesBody mass indexTreatment discontinuationAdverse eventsBodyweight reductionWeight managementGlucagon-like peptide-1 receptor agonistsInteractive web response systemPeptide-1 receptor agonistsGlucose-dependent insulinotropic polypeptideComputer-generated random sequenceFrequent adverse eventsPlacebo-controlled trialSerious adverse eventsIncretin-based therapiesPhase 3 trialWeb response systemTreatment of obesityWeekly tirzepatideCoprimary endpointsRescue therapySafety endpointWeek 72Safety profileStudy treatmentRetatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
Rosenstock J, Frias J, Jastreboff A, Du Y, Lou J, Gurbuz S, Thomas M, Hartman M, Haupt A, Milicevic Z, Coskun T. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. The Lancet 2023, 402: 529-544. PMID: 37385280, DOI: 10.1016/s0140-6736(23)01053-x.Peer-Reviewed Original ResearchConceptsGlucose-dependent insulinotropic polypeptideType 2 diabetesGLP-1 receptor agonistsEscalation groupPhase 2 trialReceptor agonistDulaglutide groupPlacebo groupStudy treatmentGLP-1Interactive web response systemModerate gastrointestinal adverse eventsType 2 diabetes managementCurrent consensus guidelinesGastrointestinal adverse eventsWeb response systemPhase 1 studyStudy site personnelHealth care centersGlucagon receptor agonistPhase 3 programRange of dosesPhase 2 dataBaseline HbAGlycaemic targets
2022
Clinical implications of Type 2 diabetes on outcomes after cardiac transplantation
Chouairi F, Mullan C, Ahmed A, Bhinder J, Guha A, Miller P, Jastreboff A, Fuery M, Chiravuri M, Geirsson A, Desai N, Maulion C, Sen S, Ahmad T, Anwer M. Clinical implications of Type 2 diabetes on outcomes after cardiac transplantation. PLOS ONE 2022, 17: e0273111. PMID: 36516178, PMCID: PMC9750001, DOI: 10.1371/journal.pone.0273111.Peer-Reviewed Original ResearchConceptsPost-transplant mortalityType 2 diabetesAllocation system changeOld allocation systemsHeart transplant recipientsOutcomes of patientsOrgan Sharing databaseProportion of patientsHeart transplantation outcomesLower likelihoodLikelihood of transplantationHigher likelihoodNew allocation systemCardiac transplantationHeart transplantationTransplant recipientsT2D patientsHeart failureSharing databaseCox regressionTransplantation outcomesUnited NetworkWorse outcomesT2DPatients
2019
Clinical Considerations Regarding the Use of Obesity Pharmacotherapy in Adolescents with Obesity
Srivastava G, Fox CK, Kelly AS, Jastreboff AM, Browne AF, Browne NT, Pratt JSA, Bolling C, Michalsky MP, Cook S, Lenders CM, Apovian CM. Clinical Considerations Regarding the Use of Obesity Pharmacotherapy in Adolescents with Obesity. Obesity 2019, 27: 190-204. PMID: 30677262, PMCID: PMC6449849, DOI: 10.1002/oby.22385.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsIntensive lifestyle interventionObesity pharmacotherapyLifestyle interventionSevere obesityPrediabetes/type 2 diabetesObesity-related comorbid diseasesNonalcoholic fatty liver diseasePediatric primary care providersIntensive lifestyle modificationFatty liver diseaseMore effective treatment strategiesObstructive sleep apneaEffective treatment optionPrimary care providersType 2 diabetesEffective treatment strategiesLifestyle modificationPharmacotherapy optionsBariatric surgeryComorbid diseasesLiver diseaseSleep apneaTreatment algorithmExcess adiposityInformed consent regulations
2014
Leptin Is Associated With Exaggerated Brain Reward and Emotion Responses to Food Images in Adolescent Obesity
Jastreboff AM, Lacadie C, Seo D, Kubat J, Van Name MA, Giannini C, Savoye M, Constable RT, Sherwin RS, Caprio S, Sinha R. Leptin Is Associated With Exaggerated Brain Reward and Emotion Responses to Food Images in Adolescent Obesity. Diabetes Care 2014, 37: 3061-3068. PMID: 25139883, PMCID: PMC4207200, DOI: 10.2337/dc14-0525.Peer-Reviewed Original ResearchConceptsLow-calorie foodsBrain responsesFood imagesEmotion processingEmotion responsesAdolescent brainNeural responsesNeural activationHigh-calorie food consumptionFood cravingsNeural alterationsBrain rewardFunctional MRIAdolescent obesityRisk of overconsumptionAdolescentsObesity-related metabolic changesEndogenous leptin levelsFood advertisingMetabolic changesYouthDevelopment of obesityType 2 diabetesLean adolescentsNation's youthInsulin: Food for Thought
Jastreboff A. Insulin: Food for Thought. Science Translational Medicine 2014, 6 DOI: 10.1126/scitranslmed.3008712.Peer-Reviewed Original ResearchType 2 diabetesIntranasal insulin
2013
Diabetes Shrinks the Brain
Jastreboff A. Diabetes Shrinks the Brain. Science Translational Medicine 2013, 5 DOI: 10.1126/scitranslmed.3008073.Peer-Reviewed Original Research